Dotarizine

Dotarizine is a novel Piperazine (HY-B0912) derivative and antimigraine agent. Dotarizine exhibits Ca2+ channel blocking properties. Dotarizine decreases the release of lactate dehydrogenase. Dotarizine shows 5-HT receptor blocking effect[1].

Product Specifications

CAS Number

[84625-59-2]

UNSPSC

12352005

Target

5-HT Receptor; Calcium Channel; Drug Derivative; Lactate Dehydrogenase

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Smiles

N1(C(C2=CC=CC=C2)C3=CC=CC=C3)CCN(CCCC4(C5=CC=CC=C5)OCCO4)CC1

Molecular Formula

C29H34N2O2

Molecular Weight

442.59

References & Citations

[1]Novalbos J, et al. Effects of dotarizine and flunarizine on chromaffin cell viability and cytosolic Ca2+. Eur J Pharmacol. 1999 Feb 5;366 (2-3) :309-17.